Home / Transcripts / Heron Therapeutics, Inc. (HRTX) · May 11, 2026

Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary

May 11, 2026

NASDAQ US Health Care Biotechnology earnings 34 min

What were the key takeaways from Heron Therapeutics, Inc.'s May 11, 2026 earnings call?

In Q1 2026, Heron Therapeutics reported net revenues of $34.7 million, slightly below expectations due to seasonal headwinds and severe weather impacting elective surgeries. The company maintained its full-year guidance of $173 million to $183 million in net product sales and adjusted EBITDA of $10 million to $20 million. Management highlighted a strong recovery in March with net sales exceeding $15 million, indicating potential for improved performance in the upcoming quarters.

What topics did Heron Therapeutics, Inc. cover?

What were Heron Therapeutics, Inc.'s May 11, 2026 results?

Heron Therapeutics faces short-term challenges due to weather-related impacts on elective surgeries, but management's confidence in recovery and strong growth in its Acute Care portfolio are positive signs. The reaffirmed guidance and strategic expansions present potential catalysts for future performance, while the market stability of CINVANTI and clinical endorsements for APONVIE provide additional support for the investment thesis.

Earnings Call Speaker Segments

Melissa Jarel executive
#1

Thank you, operator, and good day to all of you. We appreciate you being with us on Heron Therapeutics' conference call today, where we'll go over the company's financial results for the first quarter 2026. Joining me from Heron are Craig Collard, Chief Executive Officer; Ira Duarte, Executive Vice President and Chief Financial Officer; Bill Forbes, Executive Vice President and Chief Development Officer; Mark Hensley, Chief Operating Officer; and Kevin Warner, Senior Vice President, Medical Affairs, Strategy and Engagement. If you're with us by phone, slides are available through the webcast, and once today's call wraps up, you can also find them on the Investor Relations page of our website. Before we get started, a quick reminder that forward-looking statements will be made by the company during this conference call. Please be aware that anything stated that isn't a historical fact counts as a forward-looking statement. That covers comments regarding the company's projections, expectations, plans, beliefs and future performance, and all of these are forward-looking statements for the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Such statements rest on judgment and analysis as of today's date and carry numerous important risks and uncertainties that might lead actual results to differ materially from what those forward-looking statements describe. The risks and uncertainties tied to the forward-looking statements made during this conference call and webcast are laid out in the safe harbor statement in today's press release as well as in Heron's public periodic filings with the SEC. Unless the law requires otherwise, Heron takes on no obligation to update these forward-looking statements so they reflect future events or actual outcomes, and it has no intention of doing so; and now I'd like to hand the call over to Craig Collard, Chief Executive Officer of Heron.

Craig Collard executive
#2

Melissa, thank you. Greetings to all, and we're glad you could join Heron Therapeutics' call covering our 2026 first-quarter results. It's a pleasure to walk through our financial performance and provide commercial news regarding the company. First, I want to highlight several notable achievements. Coming off a robust 2025 fourth quarter, we entered the new year with considerable momentum. Normally, the first quarter brings seasonal pressure tied to co-pay resets and insurance changes, and that's exactly what happened this year. That said, 2026 threw extra obstacles our way — 2 weeks of severe weather struck early in the quarter, significantly worsening the usual seasonal softness and making January the hardest month since I came to the company. That weather hit elective surgeries hardest, since those procedures are especially vulnerable to extreme conditions and dropped sharply during that stretch. Importantly, we weren't alone in this. Several publicly traded pharmaceutical and surgical companies have described the same weather-related disruption throughout January and February. The fact that this impact was so widespread across the industry confirms the headwinds we encountered came from outside forces and were short-lived, rather than pointing to any fundamental weakness in our business or markets. Despite that, the team managed things effectively. A clear rise was evident in February, and March closed out on a high note, with net sales surpassing $15 million — a sign of the business's fundamental strength and ability to bounce back. While weather conditions definitely took a toll on our Q1 results, our confidence in the year ahead remains intact. We absolutely anticipate that the elective procedures still deferred will be rescheduled at various points across the rest of 2026, generating a significant tailwind as the year unfolds; this aligns with what we've seen historically, where Q3 and Q4 are always our strongest quarters by volume, and we expect 2026 to follow suit. Now, on to our Acute Care portfolio. Compared with the prior-year period, our revenue was up 32%. ZYNRELEF posted 27% growth, while APONVIE rose by more than 50%. There are two structural factors I want to call out. First, IGNITE — the incentive initiative we run alongside our orthopedic distribution partners — has performed very well, and as a key growth driver for ZYNRELEF we will carry it forward into 2026. Second, with APONVIE we are starting to see commercial gains from its placement in the fifth consensus guidelines covering postoperative nausea and vomiting management. We view that clinical recognition as significant and expect it to provide a lasting tailwind for adoption. Later in the presentation, we'll share more specifics about what that inclusion means strategically and commercially. Now for the growth of our sales team. We're still on schedule to have it in place by Q3, and hiring efforts have already begun. We see this as a major driver of growth throughout our portfolio, and during the presentation we'll go into the strategy in greater depth. Shifting to oncology. In spite of more intense competition, CINVANTI keeps turning in a strong showing. During the quarter, CINVANTI held a 25% exit market share within the NK1 category. Although net sales moved in the same quarter-to-quarter way we typically observe, CINVANTI by itself has remained resilient, reflecting strong customer loyalty and sustained demand even with the fierce competition in this area. In Q2, a set of new accounts is joining us, and on an annualized basis we expect they could bring in more than $10 million in net revenue. We'll go into more detail on that when we get to the commercial performance update. Before handing things to Mark for that commercial performance update, I'd like to pause once more and acknowledge the whole Heron team for what they accomplished this quarter; every day we're competing hard in a tough environment, and this quarter brought additional obstacles beyond our control, but our people keep pushing ahead. At this point I'll pass the call to Mark so he can walk us through our commercial performance. Over to you, Mark.

Mark Hensley executive
#3

Appreciate that, Craig. Now turning to how the products performed, and I'll begin with the big picture on net sales for the quarter; this chart lays out quarterly net revenue for every product over the past 4 quarters. We posted total net sales of $34.7 million in Q1. Over on the Acute Care side, that's $13.6 million combined: ZYNRELEF contributed $10.2 million, APONVIE contributed $3.4 million; on the oncology side, $21.1 million combined: CINVANTI came in at $20.5 million, SUSTOL at $0.6 million, which mirrors the planned wind down we talked about earlier. You can observe the sequential dynamics for each product. Several of these are a function of ordering and channel patterns instead of shifts in underlying demand. A better picture of how all four products are being adopted can be seen in the demand unit and ordering account figures, which I'll walk through in more depth shortly. Before we examine each product's results, though, there's an important strategic point to cover on the next slide. That slide shows the net selling price per unit for the four products over the past four quarters. The Y-axis numbers aren't displayed. What matters is the direction each product is trending. Starting with ZYNRELEF, the net selling price has risen consistently during this stretch. Our pricing approach remains firm, and the J-code and NOPAIN backdrop are helping sustain that path. For APONVIE, net price has remained steady. For a product that's still growing, that's the norm — we're prioritizing getting volume out there instead of squeezing more money out of each unit. Looking at CINVANTI, the Q4 figure dips a bit compared to the quarters on either side of it, and then Q1 returns to a level that fits with our approach. The Q4 situation was just a short-term thing, and Q1 showed the usual ordering patterns through the channel after what happened in Q4. What matters more is that our fundamental pricing approach for CINVANTI is still solid and disciplined, and SUSTOL is dropping off as expected with the planned wind down. The main takeaway from this slide is simple. When it comes to our commercial products that are active, we're keeping our pricing discipline and we're not going after volume by giving away on price. That's a choice we've made on purpose. It safeguards the franchise's economics over the long haul and backs the sustained, recurring demand that we are working to establish. Moving on to ZYNRELEF. On the slide, there are 2 charts: the one on the left shows average daily units, while the one on the right shows ordering accounts. Through Q1, both kept climbing. The figure I'd focus on is a 22% increase in demand units compared with a year earlier. During Q1, the broader local anesthetic market declined on a sequential basis. Against that backdrop, ZYNRELEF grew faster than the market year-over-year and maintained its share from one quarter to the next. The underlying franchise is delivering; when it comes to reimbursement, the permanent J-code, J0668, has been in effect since October. Thanks to the NOPAIN Act rules that kicked in when 2025 began, ZYNRELEF now has the least complicated reimbursement picture it's seen since we launched. Under that structure, about 110 million covered lives on the commercial side benefit from a more streamlined process. After two quarters, talks about reimbursement go more smoothly, and the friction we see at the billing office level keeps dropping. Now, looking at the right side of this slide, which shows what will drive things from Q2 through Q4: IGNITE will continue all the way through 2026, and we've expanded it via IGNITE 2.0, which I'll cover on the next 2 slides. Beyond that, we're watching penetration grow inside accounts — that is, additional surgeons at every institution that has adopted ZYNRELEF are bringing it into their protocols. On top of that, during Q3 2026 we will grow the ZYNRELEF sales force, in selected geographies where all 3 foundational drivers are completely established: formulary access, the IGNITE program, and payer coverage. That growth runs in parallel with the aprepitant team build-out, which I'll discuss on the APONVIE slide — a sign of how confident we are in where both franchises are heading. Further out, our prefilled syringe presentation sits in late-stage development. Bill will go into that in greater depth later on. Let's move to Slide 10. Here's the information behind IGNITE 1.0. On this chart, you can see ZYNRELEF unit volume across our IGNITE targeted accounts, with pre-IGNITE and post-IGNITE shown side by side. We started at approximately 9,000 units during the final quarter of last year prior to IGNITE, and by Q4 of last year we had climbed past 19,000 units. Among those targeted accounts, that equals 111% growth across just two quarters of the program. This is what convinced us to carry IGNITE through 2026 and broaden it even more. Slide 11 shows how IGNITE 2.0 is structured. During the second half of 2025, IGNITE 1.0 reached 2,261 accounts. IGNITE 2.0, live now for the entire year of '26, reaches 3,109 accounts. That works out to 38% higher, which brought 848 more accounts into the program. With a bigger set of participating accounts, distributors can concentrate more of their attention on the institutions we've flagged as having the greatest likelihood of picking up ZYNRELEF and expanding its use. The same structural factors behind the 111% unit growth in IGNITE 1.0 are now being brought to bear on a substantially expanded account base in 2026. At this point I'll hand things over to Bill, who will discuss the prefilled syringe.

Bill Forbes executive
#4

Thanks, Mark. On this slide, you can see how much momentum our Acute Care franchise has built, along with the steady progress being made on the ZYNRELEF prefilled syringe initiative. Adoption has been consistent and is speeding up across the platforms we use to prepare devices as we move away from the vented vial spike, or VVS, toward the much better vial access needle, or VAN. That change has gotten a warm reception and shows obvious gains in how easy the product is to use and how efficiently workflows run. Meanwhile, what the market wants keeps moving toward ready-to-use systems, and those are becoming a key growth driver as hospitals put a premium on efficiency, safety and smoother operating room workflows. Forecasts from independent third parties back up how lasting this trend is, with prefilled syringe uptake projected to expand considerably over time. Looking at the program itself, the ZYNRELEF PFS has full funding and is proceeding as planned. It was built to match what today's health systems expect, covering guidance from both ASHP and the Joint Commission, while also making operating room workflows better, cutting down preparation steps and reducing the chance of medication errors and contamination. The development program is at an advanced stage. Registration batches are manufactured and have been put on stability, and we are still on schedule to produce 12-month stability data during the first quarter of 2027. Mark, back over to you.

Mark Hensley executive
#5

Appreciate that, Bill. Turning now to APONVIE. This slide contains a pair of charts — average daily units sit on the left side, while ordering accounts are on the right. Through Q1, both demonstrated a continued, steady climb upward; looking at the Q1 metrics, demand units for APONVIE rose 68% compared with a year earlier. Average daily units were up 70% versus Q1 of the prior year; when we closed out Q1, March showed 371 ordering accounts. For this product, that marks an all-time peak, and it represents a 67% increase relative to March a year ago. Additionally, APONVIE now holds P&T approval across 1,903 accounts, which works out to 5.8 million medium to high-risk procedures each year. That final figure captures how large the addressable opportunity is that APONVIE has now been formally cleared into. Regarding upcoming growth drivers, a permanent product-specific J-code for APONVIE went live on April 1, and having that dedicated permanent billing code in place strips away one layer of reimbursement complexity for the product. During Q3 2026, we intend to grow our dedicated aprepitant sales force. At present, that team handles both APONVIE and CINVANTI, and by expanding it we add capacity that supports both products. Finally, APONVIE earned a prominent spot in the fifth consensus guidelines covering management of postoperative nausea and vomiting. That represents a meaningful clinical catalyst. I'll pass things to Kevin so he can take you through the guidelines and explain what they mean for the product.

Kevin Warner executive
#6

Thanks, Mark. We figured it would help to walk the Street through a brief explanation of why the fifth consensus guidelines for managing postoperative nausea and vomiting — which have just come out — carry such significance, clinically and economically speaking. A major shift in perioperative care is what these guidelines represent: instead of addressing PONV only once it appears, the emphasis now falls far more on getting ahead of it, with prevention as the priority and the patient at the center. From our vantage point in medical affairs, guideline updates matter a great deal, because they often turn into the foundation for enduring institutional change. Historically, adoption comes about slowly, through educating providers, EMR order sets, anesthesia workflows, perioperative pathways, and treatment algorithms. Once these practices become embedded in institutional protocols, they usually harden into highly enduring standards of care. One thing that stands out is that the updated guidelines placed considerably more emphasis on the part the NK1 antagonist plays in multimodal prophylaxis approaches. Therapies built around aprepitant, including APONVIE, received an A1 evidence rating for PONV prevention in adults — the highest tier of evidence covering both how well they work and how safe they are. The guidelines specifically name APONVIE, describing it as the first and only FDA-approved IV push NK1 antagonist with an indication for preventing PONV in adults. We believe that unique status has real clinical significance, because it combines effectiveness, smoother workflow, and straightforward perioperative use in a way that serves both providers and patients. A further important change in the guidelines is the wider recommendation favoring multimodal prophylaxis. Patient and procedure-specific risk stratification still sits at the center, but the revised guidance acknowledges that the upside of prophylaxis frequently exceeds the downside of undertreatment. Consequently, many institutions are anticipated to move toward a more liberal prophylaxis approach covering broader patient populations. The guidelines specifically advise that patients having more than two risk factors — which accounts for about half of the surgical population — receive 3 to 4 prophylactic interventions. Such medium and high-risk patients frequently need highly effective antiemetic strategies that avoid introducing recovery-limiting adverse effects. We think APONVIE occupies a uniquely favorable position here. Its effectiveness, together with a safety picture unlike that of many antiemetics in common use, makes it a good fit for patients where prevention is the top priority. A key point: APONVIE provides antiemetic coverage without causing sedation and without interfering with recovery after surgery — a benefit that matters more and more in enhanced recovery programs and outpatient procedures. One of the biggest changes in the Fifth Edition guidelines was greater attention to post-discharge nausea and vomiting, or PDNV. According to the guidelines, PONV should not be viewed only as a short-term complication occurring in the PACU. Many patients develop symptoms once they have gone home, a time when it is harder to reach clinical support. According to the guidelines, the data they cite shows about 37% of patients could deal with PDNV, and that brings problems like dehydration, issues with wounds, unplanned use of health care, and potentially being readmitted. Since the number of outpatient surgeries continues to rise and going home the same day is becoming more usual, these later complications carry greater weight in value-based care models. A significant point is that the guidelines now recommend giving prophylactic long-acting antiemetics before discharge to patients who are at risk for PDNV. Our view is that APONVIE aligns nicely with this recommendation, because it works for 48 hours and can provide extended receptor coverage across the vulnerable period after discharge. These revised recommendations also highlight several important distinctions related to APONVIE and to MK1 antagonist treatment more broadly. Administering APONVIE is as simple as giving a 30-second IV push. It works quickly, achieving at least 97% receptor occupancy within 5 minutes, and it fits easily into standard anesthesia workflows. This is particularly important for clinicians who don't have enough time before surgery, or lack oral alternatives, or are treating patients who can't take oral medications — for example, those with gastroparesis, GLP-1 use, diabetes-related GI dysfunction, or delayed gastric emptying. The guidelines also highlighted how strong the evidence is for aprepitant-based treatment: several randomized trials demonstrated that aprepitant is equal or superior to ondansetron when it comes to preventing PONV. A meta-analysis found significant reductions in PONV risk whether it's used alone or within multimodal regimens. And a sizable Cochrane systemic review assessing close to 100,000 patients placed aprepitant as the single most effective antiemetic. Significantly, the revised guidelines treat PONV prevention not merely as an effort at patient comfort, but as a genuine clinical quality and operational concern. When PONV is poorly controlled, it drives longer PACU stays, greater use of rescue medication, postponed discharge, dehydration, wound stress, aspiration concerns and readmissions. Across numerous high-risk procedures, such as abdominal bariatric, ENT, ophthalmology and other belt-up surgeries, stopping vomiting is regarded as critically important for safeguarding surgical outcomes and patient safety. Proper prophylaxis likewise aids perioperative operational efficiency through less nursing burden, fewer recovery delays, better throughput and higher satisfaction for both patients and staff. The guidance also highlighted how worthwhile it is, from a pharmacoeconomic angle, to prevent episodes effectively. Among the measures discussed was the number needed to treat, or NNT. When aprepitant was combined with dexamethasone, the NNT reported was 3.8 — put another way, treating about four patients stops one extra instance of PONV. Compared with a lot of the antiemetics in common use, that makes for an extremely attractive value proposition. Seen through the lens of a health system, the clinical and financial significance becomes apparent fast. Each single PONV episode has been projected to run around $1,000, factoring in rescue therapy, nursing time, longer PACU stays and later discharge. From that perspective, if you can stop complications with a treatment that runs about $60 a dose, that starts to look like a very sensible and easy-to-grasp choice for both providers and institutions, especially since value-based care models are putting more and more weight on how satisfied patients are, how quickly they move through the system, whether they come back, how well they recover and what the whole episode of care ends up costing. Ultimately, our view is that the fifth consensus guidelines bolster a handful of significant macro trends that are defining perioperative care: wider adoption of multimodal prophylaxis, a growing awareness of nausea and vomiting that occurs after discharge, the ongoing shift of procedures to outpatient settings, a push for smoother workflow, and rising demand for therapies that are safe, effective, nonsedating and long-acting to underpin enhanced recovery pathways — and we see APONVIE as uniquely suited to meet that need. I'll hand things back over to Mark now so he can walk us through the oncology supportive care franchise.

Mark Hensley executive
#7

Thanks for that, Kevin. Let's turn now to the supportive care side of oncology. There are two charts on this slide — the one on the left shows average daily units, and the one on the right shows ordering accounts. When it comes to CINVANTI, average daily units have held up well, keeping a consistent usage trend throughout 2024 and continuing into 2026. For a product that's already in the mature stage commercially, in a space that's faced relentless competitive pressure, that's a sign of real staying power. As for ordering accounts, the chart on the right has two layers. The blue line is existing accounts, which come in at about 1,100 every month — a reflection of just how loyal that customer base is. The purple line shows accounts that are either new or coming back, and during the first quarter of 2026 those averaged roughly 59 each month. If we zoom in on March, orders for CINVANTI came from 1,188 accounts, a number that was in line with the roughly 1,200 accounts we see on average over 12 months. Turning to market share, CINVANTI closed out Q1 with a 25% exit share for March 2026. Again, that was consistent with what we see across a 12-month average. The main point to take away is stability. In a category where competition persists, we are holding our ground. Regarding what will fuel expansion for the rest of 2026, Greg brought up several fresh accounts that are set to launch during this year. Those added formulary victories originate from our REIGNITE initiative, which is focused on securing CINVANTI availability at large teaching hospitals — there, we have already secured formulary wins — and the opportunity in the near term amounts to roughly $10 million. Also, as I said before, expanding our committed aprepitant sales team during 2026's third quarter will provide backing for both CINVANTI and APONVIE. CINVANTI will be promoted by that group in the second position. Now let's move to the wider category trends. On the following slide, the chart shows the overall NK1 category for chemotherapy-induced nausea and vomiting over the trailing 12 months. In the stacked bars, you can see total category units split out by each competing product. The percentages sitting on top of those bars show how much the overall category moved from one month to the next, ranging anywhere from a 19% decline in some months to a 21% gain in others. CINVANTI's share of that category is what the line running across the chart tracks. Even with all that movement at the category level, CINVANTI's share has held incredibly steady. Looking at the 12-month average, it comes to 25%. As of March 2026, we closed at 25%, and that steadiness of share, in a category where the underlying volume swings so sharply month to month, is what marks the durability of this franchise. Wrapping up the commercial section: ZYNRELEF demand was up 22% versus a year ago, and with IGNITE 2.0 we're expanding our targeted account base by 38% for 2026. APONVIE demand rose 68%. We hit a record number of ordering accounts, and the fifth consensus guidelines now recognize the product as the evidence-graded standard for PONV prophylaxis. In a category that's been volatile, CINVANTI kept a steady 25% market share, while reignite is building roughly $10 million of near-term pipeline. Through all of this, our pricing discipline remains intact. Our structural drivers are in place, our commercial leverage keeps growing, and both our ZYNRELEF team and our dedicated aprepitant team are set to expand in Q3. The initiatives we launched during 2025 are delivering exactly as we intended, and we have a clear line of sight to hitting the full-year framework we laid out back in February. With that, I'll turn it over to Ira.

Ira Duarte executive
#8

Thanks, Mark. Just like Craig mentioned, the results we posted for this quarter landed slightly under what we had planned. That being said, although winter storms aren't something we can control, the way we run our business in reaction to them absolutely is. And keeping a tight grip on costs continues to be something this team is known for — something our shareholders have grown to count on. For the quarter, net revenues reached $34.7 million, and gross margin landed at 69%, which is beneath the low to mid-70s percent range we normally see. As we've talked about on earlier calls, we have a secondary supplier for CINVANTI and were bound by a contractual obligation to make a specific amount of inventory across the last year. That secondary product gets made in smaller batch sizes, costing roughly 3x per batch compared with our primary supplier. Over the coming two quarters, this inventory will move through our system, and after that we'll go back to using only our primary supplier. Once those contractual duties are met, we anticipate gross margins returning to normal in the mid-70% range. Adjusted EBITDA for the quarter was negative $727,000, which captures the joint effect of the revenue softness tied to the storms and the short-term gross margin strain caused by our secondary CINVANTI supplier. Neither of these factors is permanent, and we anticipate adjusted EBITDA getting back into positive territory as 2026 progresses. Going forward, the rebound has already begun. As was mentioned earlier during this call, March net revenues climbed back above $15 million — a robust indicator for the second quarter and one that strengthens our belief that we'll hit our full year targets. To restate our 2026 guidance, we're holding net product sales at $173 million to $183 million along with adjusted EBITDA of $10 million to $20 million, which reflects ongoing profitability together with significant commercial growth. With all that said, we'd be glad to take your questions now.

Brandon Folkes analyst
#9

I might just have a small number of items for you. To begin with, regarding the guidance you provided, could you discuss a few of the factors that could help or hinder ZYNRELEF, which you're counting on to hit the revenue target for the whole company? Are you factoring in ZYNRELEF gaining share of the market? Then, second, I apologize if this was covered already. Could you share a bit more about the Baxter settlement — what it permits, and what kind of exclusivity it maintains? That covers my questions. Actually, perhaps one additional item — you brought up friction. So could you explain the way you substantially alter the adoption trajectory for both ZYNRELEF and APONVIE; and regarding ZYNRELEF, it seems there's friction at the point where an office has to make the call to use ZYNRELEF. What's your approach to changing that before the prefilled syringe arrives, and to removing the friction that exists right now, so the prefilled syringe is able to capture as much value as possible?

Craig Collard executive
#10

Brandon, I appreciate those questions. I'll begin with the Baxter settlement, after which I'll hand things to Mark. Given what the settlement stipulates, we truly cannot elaborate on it beyond noting the dates and all other information already made public; apart from that, we are simply prohibited from commenting further on it; therefore I'll pass it to Mark so he can address the ZYNRELEF topics you raised.

Mark Hensley executive
#11

Yeah, that's a really good question. I'd say items 1 and 3 are sort of intertwined — they go hand in hand. When it comes to how confident we feel, though, there are a number of things we're considering. To start, we mentioned the weather, along with elective procedures getting pushed out of January. Naturally, our expectation is that those procedures will get rescheduled at some point across the year. So that should definitely serve as a solid tailwind for us. When it comes to ZYNRELEF as well as APONVIE, our main focus is on growing the sales force around the middle of the year; we do believe that's going to boost our share of voice and really allow us to build on the foundation we've already established; and then there's IGNITE 2.0 — you can look at the slides and see what it produced during the third and fourth quarter of last year. So growing that by 38% in 2026, in our view, will be another really strong tailwind as we move ahead. Then, on the friction side, from where we sit, we don't actually come across accounts that are unwilling to use ZYNRELEF. Honestly, what's toughest for us is reaching a large enough number of them to generate the sort of quarter-over-quarter growth we'd like to see from the product, correct? That's largely why we're growing the team around the middle of the year. And of course, that share of voice is going to keep increasing. So — since we keep watching market share climb within our targeted accounts, definitely among the accounts we're aligned with, not just at Heron, but through our IGNITE program as well. So we simply want to keep building on that nationwide.

John Gionco analyst
#12

This is John filling in for Serge. To start, I'd like to revisit ZYNRELEF regarding those first-quarter winter storm challenges. I'm wondering whether you can put a number on how much surgical volumes were affected during that period. Then, secondly, regarding NOPAIN's rollout — clearly it's been available for more than 12 months at this point. I'd like to know what effect you're observing when it comes to commercial coverage, how that's evolved as time has passed, and what your expectations are looking toward '26. And then, if I can fit in one more about the CrossLink partnership — it appears you're building on the original IGNITE program, aiming at additional accounts in '26. I'm wondering whether this is simply applying additional resources to the program so you can reach more accounts, and what other developments we should anticipate on that front?

Mark Hensley executive
#13

Thank you for those questions. Regarding surgical volume, according to our data, we're seeing roughly a high single-digit drop versus the fourth quarter. That's a fairly substantial effect, bigger than what prior years showed us; we attribute it partly to weather, partly to a record Q4 in terms of surgical volume, and perhaps some of our surgical partners simply pausing to catch their breath during the quarter. That said, we certainly anticipate a significant rebound. And clearly, regarding those procedures that didn't happen, our expectation would be that they get rescheduled. On your second question about commercial coverage — clearly, NOPAIN is a tremendous asset for ZYNRELEF and definitely eliminates what I've referred to as friction, at least when it comes to the Medicare side, the government payer side. Since it was implemented, an increasing number of commercial payers have started adding ZYNRELEF beyond the surgical bundles, reimbursing outside of that bundle. We gave the figure during the call: 110 million lives represents our estimate on the commercial side. So broadly throughout the United States, ZYNRELEF coverage is quite strong. There are certain regions where ZYNRELEF remains bundled, but we certainly can step in and hold those discussions at the payer level; and generally speaking, they're open to listening and adjusting things for our patients. As for CrossLink, we let them choose the accounts; because of that, the natural selection resulted in an expansion of that program, again, at 38%; so the alignment between Heron and CrossLink is now close to 90% in terms of where we're focused. That's the highest level it has ever reached, considerably above the back half of 2025. What that ultimately means is we have a Heron employee present in the account. We have a CrossLink employee present in that account; we have very solid payer coverage in those accounts; that's the reason they were chosen; so those three components together have demonstrated to us that this is where we achieve real success and can keep advancing ZYNRELEF. This, therefore, leaves us feeling quite assured about 2026.

Craig Collard executive
#14

Thanks, operator. I’d simply like to express appreciation to each of you for being on today’s call, and we’re eager to talk with all of you again in the next quarter.

Operator operator
#15

And this concludes today's program. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.